Search Results - "Hirshfield, K"

Contribution of serine, folate and glycine metabolism to the ATP, NADPH and purine requirements of cancer cells by Tedeschi, P M, Markert, E K, Gounder, M, Lin, H, Dvorzhinski, D, Dolfi, S C, Chan, L L-Y, Qiu, J, DiPaola, R S, Hirshfield, K M, Boros, L G, Bertino, J R, Oltvai, Z N, Vazquez, A

“…Recent observations on cancer cell metabolism indicate increased serine synthesis from glucose as a marker of poor prognosis. We have predicted that a fraction…”
Get full text

KEYNOTE-756: Randomized, double-blind, phase III study of pembrolizumab vs placebo + neoadjuvant chemotherapy (CT) and adjuvant endocrine therapy (ET) for high-risk, early-stage estrogen receptor–positive human epidermal growth factor receptor 2–negative (ER+/HER2−) breast cancer (BC) by Cardoso, F., Jia, L., Hirshfield, K., Karantza, V.

Get full text

Landscape of RAF1 fusions in solid tumors and therapeutic utility of sorafenib by Mehnert, J, Ali, S, Kulkarni, A, Pavlick, D, Goydos, J, Chen, S, Shrock, A, Hirshfield, K, Rodriguez, L, Stein, M, White, E, Ross, J, Miller, V, Stephens, P, Ganesan, S

“…Background: Fusions involving the RAF1 (cRAF) kinase have been reported in several solid tumors as likely driver mutations. We now present the landscape of…”
Get full text

2879 High prevalent BRAF alterations and tert promoter mutations in papillary thyroid carcinoma by Wang, K, Ganesan, S, Johnson, A, Sharman, J.P, Chachoua, A, Hirshfield, K, Aisner, J, Yelensky, R, Lipson, D, Elvin, J.A, Chmielecki, J, Stephens, P.J, Ross, J.S, Miller, V.A, Ou, S.H.I, Ali, S.M

Get full text

Evaluation of Single Nucleotide Polymorphisms (SNP) in the P53 Binding Protein Gene (TP53BP1), in Breast Cancer Patients Treated with Breast Conserving Surgery and Whole-breast Irradiation (BCS+RT) by Haffty, B.G, Goyal, S, Green, C, Schiff, D, Yang, Q, Moran, M.S, Kulkarni, D, Ganesan, S, Hirshfield, K

Get full text

121TiPKEYNOTE-756: Randomized, double-blind, phase III study of pembrolizumab vs placebo + neoadjuvant chemotherapy (CT) and adjuvant endocrine therapy (ET) for high-risk, early-stage estrogen receptor–positive human epidermal growth factor receptor 2–negative (ER+/HER2−) breast cancer (BC) by Cardoso, F, Jia, L, Hirshfield, K, Karantza, V

Get full text

PCN240 Healthcare Resource Utilization Associated with Disease Recurrence Among Surgically-Treated Patients with Triple-Negative Breast Cancer by Sieluk, J., Haiderali, A., Huang, M., Hirshfield, K., Signorovitch, J., Song, Y., Freimark, J., Berman, R.

Get full text

PCN248 Productivity Costs Associated with Disease Recurrence Among Surgically-Treated Patients with Triple-Negative Breast Cancer by Sieluk, J., Haiderali, A., Huang, M., Hirshfield, K., Signorovitch, J., Song, Y., Freimark, J., Wang, T.

Get full text

Single-nucleotide polymorphisms in the p53 pathway by Harris, S L, Gil, G, Hu, W, Robins, H, Bond, E, Hirshfield, K, Feng, Z, Yu, X, Teresky, A K, Bond, G, Levine, A J

“…A cell culture assay has been developed that detects and validates single-nucleotide polymorphisms (SNPs) in genes that populate the p53 pathway. One hundred…”
Get full text

KEYNOTE-756: A randomized, double-blind, phase III study of pembrolizumab or placebo with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early-stage, ER+/HER2−breast cancer by Cardoso, F., Bardia, A., André, F., Cescon, D.W., McArthur, H., Telli, M., Loi, S., Cortes, J., Schmid, P., Harbeck, N., Denkert, C., Jackisch, C., Jia, L., Hirshfield, K., Karantza, V.

Get full text

Abstract P1-05-07: Comprehensive genomic profiling of clinically malignant phyllodes tumors of the breast reveals frequent mutation of NF1 and other genes associated with PI3K and RAS pathway activation by Gay, LM, Elvin, JA, Vergilio, J-A, Suh, J, Ramkissoon, S, Ali, S, Schrock, A, Hirshfield, K, Ganesan, S, Miller, VA, Stephens, PJ, Ross, JS

“…Abstract Background: Malignant or metastatic breast phyllodes tumors (MPT) are exceptionally rare, and the underlying genomic drivers are still being…”
Get full text

Dynamic fluorescence measurements of two-state systems: applications to calcium-chelating probes by Hirshfield, K M, Toptygin, D, Packard, B S, Brand, L

“…A fluorescence technique for characterizing ligand binding is evaluated. This technique uses the combination of steady-state and time-resolved methods to…”
Get more information

435 - Landscape of RAF1 fusions in solid tumors and therapeutic utility of sorafenib by Mehnert, J., Ali, S., Kulkarni, A., Pavlick, D., Goydos, J., Chen, S., Shrock, A., Hirshfield, K., Rodriguez, L., Stein, M., White, E., Ross, J., Miller, V., Stephens, P., Ganesan, S.

Get full text

A polymorphism in the 3′UTR region of E-cadherin associates with recurrence of breast cancer by Hirshfield, K. M., Kulkarni, D., Kostialik, J.

“…Abstract only…”
Get full text

Detection of Functional Single-Nucleotide Polymorphisms That Affect Apoptosis by Harris, Sandra L., German Gil, Robins, Harlan, Hu, Wenwei, Kim Hirshfield, Elisabeth Bond, Gareth Bond, Levine, Arnold J.

“…Human EBV-transformed B lymphocyte cell lines (LCLs) were used to measure the apoptotic response of individuals to γ radiation. The responses form a normal…”
Get full text

Steady-state and time-resolved fluorescence measurements for studying molecular interactions: interaction of a calcium-binding probe with proteins by Hirshfield, Kim Marie, Toptygin, Dmitri, Grandhige, Gopal, Kim, Hans, Packard, Beverly Z., Brand, Ludwig

“…The binding of 2-[(2-bis[carboxymethyl]amino-5-methylphenoxy)-methyl]-6-methoxy-8-bis[carboxymethyl] aminoquinoline, the fluorescent calcium probe Quin2, to…”
Get full text

A nanosecond fluorescence study of the simultaneous influx of Ca2+ and Cd2+ into liposomes by Hirshfield, K M, Toptygin, D, Grandhige, G, Packard, B Z, Brand, L

“…Nanosecond fluorescence decay characteristics of the calcium-binding probe Quin2 and two of its cation complexes were examined by time-resolved fluorescence…”
Get full text

EE458 Economic Burden of Disease Recurrence in Elderly Patients With Human Epidermal Growth Factor Receptor 2-Negative (HER2–) Early Breast Cancer (eBC) by Earla, JR, Kurian, AW, Kponee-Shovein, K., Song, Y, Mahendran, M, Hua, Q, Hilts, A, Hirshfield, KM, Mejia, JA

Get full text

Abstract P1-15-14: Neoadjuvant liposomal doxorubicin and carboplatin is effective and tolerable for the treatment of triple negative breast cancer by Chan, N, Riedlinger, GM, Lu, S-e, Pham, KT, Kirstein, LJ, Eladoumikdachi, FG, George, MA, Potdevin, LB, Kowzun, MJ, Desai, SA, Tang, DM, Omene, CO, Wong, ST, Rodriguez-Rust, L, Kumar, S, Kearney, TJ, Liu, C, Ganesan, S, Toppmeyer, DL, Hirshfield, KM

“…Abstract Background: The use of neoadjuvant platinum with taxane for triple negative breast cancer (TNBC) has gained increased attention for improving rates of…”
Get full text

Abstract P3-07-02: Are we missing actionable targets in breast cancer? Novel insights into recurrent Ret alterations by Hirshfield, KM, Paratala, BS, Hindoyan, A, Dolfi, SC, Yilmazel, B, Schrock, A, Gay, L, Ali, SM, Ross, JS, Williams, CB, Nair, P, Ganesan, S, Leyland-Jones, B

“…Abstract Background: Recurrent gene fusions in breast cancer have been rarely reported suggesting that they either are not present or are not easily detected…”
Get full text